Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non–small cell lung cancer

Abstract Background Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer (NSCLC), yet reliable biomarkers beyond programmed death-ligand 1 (PD-L1) expression remain limited. Increasing evidence links the gut microbiome to ICI activity, but the predictive...

Descripció completa

Dades bibliogràfiques

Autors principals:	Silvia Cavaliere, Marta Fogolari, Michele Iuliani, Simone Foderaro, Alessio Cortellini, Sonia Simonetti, Emanuele Claudio Mingo, Silvia Calagna, Marco Russano, Bruno Vincenzi, Giuseppe Tonini, Silvia Angeletti, Francesco Pantano
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-01-01
Col·lecció:	Journal of Translational Medicine
Matèries:	Salivary microbiome Immune-checkpoint inhibitors Non–small cell lung cancer Actinomyces
Accés en línia:	https://doi.org/10.1186/s12967-025-07570-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!